Ginkgo Bioworks Holdings
Statements
Income Statement
All figures as a percentage of revenue in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| 12.5% | 19.0% | 24.3% | 24.4% | 11.2% | 21.9% | 24.9% | 29.9% | 33.0% | -24.4% | 81.6% | 8.5% | 19.9% | |
| 87.5% | 81.0% | 75.7% | 75.6% | 88.8% | 78.1% | 75.1% | 70.1% | 67.0% | 124.4% | 18.4% | 91.5% | 80.1% | |
| 282.6% | 336.8% | 359.6% | 238.8% | 86.5% | 174.2% | 146.8% | 107.6% | 178.6% | 150.1% | 256.3% | 229.3% | 192.7% | |
| 148.0% | 256.7% | 185.2% | 117.9% | 58.7% | 130.7% | 101.5% | 87.2% | 115.8% | 137.8% | 194.3% | 152.7% | 142.7% | |
| 604.2% | 593.5% | 544.9% | 472.2% | 150.8% | 314.3% | 259.2% | 202.2% | 298.8% | 336.3% | 384.9% | 381.9% | 340.0% | |
| -516.7% | -512.5% | -469.1% | -396.7% | -62.0% | -236.3% | -184.1% | -132.1% | -231.8% | -211.9% | -366.5% | -290.5% | -259.9% | |
| – | 0.3% | – | – | – | 0.2% | – | – | – | – | – | – | – | |
| -546.5% | -609.7% | -437.2% | -386.1% | -63.8% | -246.0% | -188.1% | -122.1% | -207.9% | -243.7% | -391.0% | -283.8% | -264.1% | |
| 0.0% | -0.6% | 0.1% | 0.3% | -0.4% | -0.7% | 0.2% | -0.6% | 0.0% | -1.9% | -0.4% | 0.6% | -0.5% | |
| -546.4% | -609.1% | -437.3% | -386.4% | -63.3% | -245.2% | -188.2% | -121.6% | -207.9% | -241.8% | -424.1% | -231.7% | -260.0% | |
| -305.1% | -831.2% | -403.3% | -250.3% | -39.4% | -327.2% | -141.4% | -92.9% | -171.4% | -104.4% | -325.3% | -220.1% | -187.0% |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: October 2, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.